Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed + haemophilus influenzae type b conjugate vaccine + hepatitis B vaccine recombinant + oral poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
This combination represents a hexavalent immunization regimen providing protection against six major childhood diseases: diphtheria, tetanus, pertussis, Haemophilus influenzae type b (Hib), hepatitis B, and poliomyelitis. It consists of an injectable component containing adsorbed diphtheria and tetanus toxoids, acellular pertussis antigens, recombinant hepatitis B surface antigen, and a conjugated Hib capsular polysaccharide, administered alongside an oral live-attenuated poliovirus vaccine (OPV). While modern hexavalent vaccines increasingly utilize inactivated poliovirus (IPV) in a single injection (e.g., Infanrix Hexa, Vaxelis), this specific combination using OPV has been widely employed in global health programs and clinical trials, particularly in regions where OPV remains a core component of the Global Polio Eradication Initiative. The regimen induces active immunity through a variety of mechanisms, including toxin neutralization and the induction of systemic and mucosal antibodies against viral and bacterial pathogens.
- Other names
- DTaP-HepB-Hib+OPVDTaP-Hib-HepB+OPVdiphtheria-tetanus-acellular pertussis-haemophilus influenzae type b-hepatitis B-oral polio vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)PRN (Pertactin)HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)PV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed + haemophilus influenzae type b conjugate vaccine + hepatitis B vaccine recombinant + oral poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed + haemophilus influenzae type b conjugate vaccine + hepatitis B vaccine recombinant + oral poliovirus vaccine.